Xtx Topco LTD Kronos Bio, Inc. Transaction History

Xtx Topco LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$0.82 - $1.07 $1,353 - $1,766	1,651 Added 3.98%	43,117 $40,000
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.5 $7,769 - $12,667	-8,445 Reduced 16.92%	41,466 $41,000
Q2 2024 Aug 12, 2024	BUY	$0.73 - $1.38 $6,640 - $12,552	9,096 Added 22.29%	49,911 $61,000
Q1 2024 May 13, 2024	BUY	$1.02 - $1.3 $8,958 - $11,417	8,783 Added 27.42%	40,815 $53,000
Q4 2023 Feb 13, 2024	BUY	$0.75 - $1.49 $8,113 - $16,118	10,818 Added 50.99%	32,032 $40,000
Q3 2023 Nov 13, 2023	SELL	$1.23 - $2.25 $696 - $1,273	-566 Reduced 2.6%	21,214 $27,000
Q2 2023 Aug 14, 2023	BUY	$1.24 - $1.92 $27,007 - $41,817	21,780 New	21,780 $37,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $108,675 - $259,613	-75,469 Reduced 74.98%	25,184 $40,000
Q3 2022 Nov 14, 2022	BUY	$3.35 - $5.55 $127,748 - $211,643	38,134 Added 61.0%	100,653 $337,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $195,059 - $470,142	62,519 New	62,519 $228,000

19.3M

51.2K

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $38.6M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.